Eyenovia (NASDAQ:EYEN) issued its quarterly earnings data on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.03, Bloomberg Earnings reports.
Shares of EYEN opened at $3.34 on Wednesday. Eyenovia has a 12 month low of $2.40 and a 12 month high of $6.98. The stock’s fifty day simple moving average is $3.47. The firm has a market capitalization of $55.24 million, a PE ratio of -1.84 and a beta of 1.11.
Several equities research analysts have recently issued reports on the stock. HC Wainwright set a $14.00 price objective on shares of Eyenovia and gave the stock a “buy” rating in a research report on Wednesday, June 5th. Zacks Investment Research raised shares of Eyenovia from a “sell” rating to a “hold” rating in a research report on Tuesday, June 25th. ValuEngine raised shares of Eyenovia from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Oppenheimer assumed coverage on shares of Eyenovia in a research report on Wednesday, April 24th. They set an “outperform” rating and a $9.00 price objective for the company.
An institutional investor recently bought a new position in Eyenovia stock. Bank of New York Mellon Corp bought a new position in shares of Eyenovia Inc (NASDAQ:EYEN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,529 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned about 0.11% of Eyenovia at the end of the most recent quarter. 7.88% of the stock is currently owned by institutional investors.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
See Also: What is net income?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.